By Chris Hutching
Friday 17th September 2004 |
Text too small? |
The health board contracts account for 25-30% of the company's pre-tax revenue but there were concerns after the tender dragged on for several months.
The tender is in two parts, one of which is yet to be resolved.
The board confirmed the pharmaceuticals tender, which accounts for almost 60% of the combined value of the two tenders (Ebos' subsidiary, Health Support, is the incumbent provider). A second tender for medical consumables is still being worked through, with a decision expected before Christmas.
The sale of shares by Rangatira apparently took Ebos directors by surprise, coming on the same day (last Friday) that Ebos confirmed the pharmaceuticals contract.
About one million shares were sold at $3.80 a share on the same day and another 1.7 million shares were sold via institutions and brokers at an average $3.87 a share.
But the on-market retail price hit a record $4.10 (sell) before settling back at $4.03.
No comments yet
Fletcher Building Announces Director Appointment
Meridian issues new demand response exercise notice to NZAS
CRP - Chatham Closes Private Placement of Shares
General Finance - Olympic Term Deposit Promotion featuring a Special Bonus of 0.1%
July 22nd Morning Report
VCT - Operational performance for the year ended 30 June 2024
Challenge to banks the way to go
Bigger returns or lower risk?
NPH - Director Appointment
July 19th Morning Report